Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Authors
Keywords
-
Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 78, Issue 5, Pages 421-433
Publisher
Elsevier BV
Online
2021-07-27
DOI
10.1016/j.jacc.2021.04.102
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
- (2020) Vera A. Bittner et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome
- (2020) Gregory G. Schwartz et al. CIRCULATION
- The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
- (2020) Nicholas A. Marston et al. CIRCULATION
- Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis
- (2020) Patrick M. Moriarty et al. Current Atherosclerosis Reports
- Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
- (2020) Michael Szarek et al. EUROPEAN HEART JOURNAL
- Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
- (2019) Michelle L. O'Donoghue et al. CIRCULATION
- Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among Seven Ethnic Groups
- (2019) Guillaume Paré et al. CIRCULATION
- Elevated Lipoprotein(a) and Risk of Ischemic Stroke
- (2019) Anne Langsted et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays
- (2019) Hubert Scharnagl et al. ATHEROSCLEROSIS
- Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes
- (2019) Daniel F. Gudbjartsson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Relationship of Lipoprotein(a) Molar Concentrations and Mass According to Lipoprotein(a) Thresholds and Apolipoprotein(a) Isoform Size
- (2018) Sotirios Tsimikas et al. Journal of Clinical Lipidology
- Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies
- (2018) Stephen Burgess et al. JAMA Cardiology
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
- (2018) Scott M. Grundy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium
- (2017) Christoph Waldeyer et al. EUROPEAN HEART JOURNAL
- A Test in Context: Lipoprotein(a)
- (2017) Sotirios Tsimikas JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin
- (2017) Robert P. Giugliano et al. JAMA Cardiology
- LPA Gene, Ethnicity, and Cardiovascular EventsClinical Perspective
- (2016) Sang-Rok Lee et al. CIRCULATION
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
- (2014) Gregory G. Schwartz et al. AMERICAN HEART JOURNAL
- Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts
- (2014) A. Laschkolnig et al. CARDIOVASCULAR RESEARCH
- Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease
- (2012) Deepti Gurdasani et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Lipoprotein(a)-cholesterol: A significant component of serum cholesterol
- (2011) Kiyoko Kinpara et al. CLINICA CHIMICA ACTA
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
- (2009) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started